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The extensive use and misuse of antibiotics has led to an increased emergence of 
multidrug-resistant Klebsiella pneumoniae strains. They are a serious concern worldwide 
due to their propensity to spread and the scarce effective treatments left. Consequently, 
phage therapy is garnering renewed interest as an alternative method to defeat antibiotic 
resistant bacteria. Phages – natural pathogens of bacteria – have several properties: 
high capacity to replicate and host specificity that turns them into a great advantage over 
antibiotics.  
Eight bacteriophages infecting Klebsiella pneumoniae were characterized according to 
their genetic material and morphology by performing endonuclease digestions and 
transmission electron microscopy imaging with 1% phosphotungstic acid or 2% uranyl 
acetate as staining dyes. Then, they were classified in agreement with their 
morphological characterization.  
Seven phages (EKP3P1, EKP3P2, EKP3P4, EKP3P5, EKP8P2, EKP8P3 and EKP8P4) 
were classified into Siphoviridae family showing hexagonal heads with long non-
contractile, sometimes flexible tails and closely related restriction patterns. EKP8P1 
phage was classified into Podoviridae family showing an icosahedral head with a short 
non-contractile tail and a different restriction pattern. They all belong to Caudovirales 
order. Moreover, a prophage was found in EKP8P1 sample, and classified into 
Siphoviridae family according to its morphology.  
The genome of EKP3P5 phage, a double stranded DNA of 47,622 bp long, was 
sequenced and annotated manually. EKP3P5 phage is a temperate phage encoding 
integrase, holin and endolysin proteins, among others. Therefore, EKP3P5 could not be 
used in phage therapy due to the risk of transferring virulence and resistance genes to 
the host bacteria. 
For all the above reasons, this thesis provides detailed knowledge of the physical 
structure along with genomic qualities of eight bacteriophages infecting multidrug-
resistant Klebsiella pneumoniae strains. This is important for determining the potential of 
phages as therapeutic agents and the first step to improve phage therapy. 
 
RESUMEN 
El uso inadecuado y excesivo de los antibióticos ha aumentado el número de cepas 
multiresistentes de Klebsiella pneumoniae, que constituyen un problema a nivel mundial 
por su gran capacidad de propagación y los pocos tratamientos disponibles. Por ello, se 
ha incrementado el interés hacia la fagoterapia como tratamiento alternativo en las 
enfermedades infecciosas. Los bacteriófagos – patógenos naturales de las bacterias – 
suponen una ventaja frente a los antibióticos por su alta capacidad de replicación y 
especificidad hacia el hospedador. 
Se han caracterizado ocho bacteriófagos de Klebsiella pneumoniae de acuerdo a su 
material genético, mediante enzimas de restricción, y a su morfología, analizada por 
microscopía electrónica de transmisión con tinciones de ácido fosfotúngstico al 1% y 
acetato de uranio al 2%. Se han clasificado según su morfología. 
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Siete bacteriófagos (EKP3P1, EKP3P2, EKP3P4, EKP3P5, EKP8P2, EKP8P3 y 
EKP8P4) pertenecen a la familia Siphoviridae, caracterizados por cabezas hexagonales, 
colas largas no contráctiles y en algunos casos flexibles y patrones de restricción 
similares. El bacteriófago EKP8P1 pertenece a la familia Podoviridae caracterizado por 
una cabeza icosaédrica, una cola pequeña no contráctil y un patrón de restricción 
diferente. Todos ellos pertenecen al orden Caudovirales. Además, se encontró un 
profago en la muestra de EKP8P1, perteneciente a la familia Siphoviridae. 
El bacteriófago EKP3P5 tiene un genoma de dsADN con una longitud de 47,622 pb que 
fue secuenciado y anotado manualmente. Es atemperado y en su genoma se codifican 
proteínas como la integrasa, holina o endolisina. No puede ser usado en fagoterapia por 
ser capaz de transferir genes de virulencia y resistencia a la bacteria hospedadora. 
Este trabajo ha permitido obtener un conocimiento detallado sobre la morfología y las 
propiedades genómicas de ocho bacteriófagos; información valiosa para estudiar el 
potencial de estos fagos en su uso como agentes terapéuticos y el primer paso para 
avanzar en la fagoterapia. 
2 INTRODUCTION. 
Antibiotic resistance is one of the most worrying and challenging problems around the 
world. The excessive use and misuse of antibiotics selects resistant strains leading to 
their increased emergence; this is endangering the way infectious diseases are treated 
nowadays. As a consequence, new effective treatments, such as phage therapy, need to 
be investigated to prevent and control antibiotic resistant bacterial infections; without 
them, the quality of health will decrease drastically.  
The World Health Organization classifies Klebsiella pneumoniae as a critical multidrug 
resistant bacterium. As a priority pathogen, there is a need to put much initiative and 
implication into research of new treatments. In this thesis, the main purpose is to 
characterize the physical structure and genomic qualities of Klebsiella pneumoniae 
infective phages and evaluate their potential in the phage therapy. 
2.1 CURRENT SITUATION OF ANTIBIOTIC RESISTANCE 
The World Health Organization (WHO) described antibiotic resistance as the most 
serious concern worldwide and claimed that it can imply the end of the antibiotic era. 
Antibiotic resistance is a natural phenomenon in bacteria, however, the selective 
pressure exerted by the use and misuse of antibiotics enhances it1. Up to 50% of all the 
antibiotics prescribed for people are not needed or are not optimally effective as 
prescribed2.  
Centers of Disease Control and Prevention (CDC) estimated in 2013, that there were at 
least 2,040,442 illnesses and 23,000 deaths per year in USA caused by antibiotic 
resistance. Recent publications estimate that in 2016 there were 700,000 deaths 
worldwide and that this number could rise to 10 million by the year 20502,3.  
2.2 MULTIDRUG-RESISTANCE BACTERIA: KLEBSIELLA PNEUMONIAE 
The WHO regards Klebsiella pneumoniae as a bacterium of main public health 
importance. Carl Friedländer discovered K. pneumoniae in 18834. It is a Gram-negative 
and lactose-fermenting bacillus, an opportunistic pathogen member of the family 
Enterobacteriaceae5. In addition, it is a leading cause of nosocomial infections like 
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pneumonia, sepsis and new-borns infections5, but it has the ability to cause urinary tract, 
respiratory tract and blood infections1 in patients with a compromised immune system5.  
K. pneumoniae is related to high morbidity and mortality rates6.  
Several factors are associated with K. pneumoniae virulence such as: capsular antigens, 
fimbriae, biofilm formation, O antigens and siderophores7. The capsule is the major 
virulence factor and it is usually related to the intensity and seriousness of the infection8. 
The capsule and biofilm formation protect the bacteria from being killed by the immune 
system and they also impair the diffusion of antibiotics5.  
K. pneumoniae is a source of antibiotic resistance, an adaptive feature acquired by the 
bacterium after being in contact with antibiotics9. K. pneumoniae has acquired resistance 
genes by mutations and horizontal gene transfer (HGT)10 (Image 1). Consequently, 
extended-spectrum β-lactamases (ESBLs) and carbapenemase-producing strains have 
appeared. 
Image 1: General drawing of the 
acquisition and expansion of 
antibiotic resistance. Natural 
selection is the main responsible of the 
appearance of antibiotic resistance 
strains, however mutations increase 
this feature. The excessive use and 
misuse of antibiotic select resistance 
strains. Resistance strains will multiply 
and spread by means of horizontal 





2.2.1 Extended-spectrum β-lactamases (ESBLs) and carbapenem resistance 
β-lactam antibiotics are the most used group of antibiotics (60% of worldwide antibiotic 
usage) due to their wide antibacterial spectrum and low toxicity; they were the first 
treatment for K. pneumoniae. However, their mechanism of action − blocking the cell 
wall biosynthesis − is impaired by β-lactamases such as TEM-1, TEM-2 and SHV-111.  
β-lactamases underwent mutations in their active site, which increased their resistance 
to a wider repertoire of antibiotics, leading to the appearance of extended-spectrum β-
lactamases (ESBLs). The first ESBL gene identified was SHV-2 followed by TEM-312, 
currently there are many versions of them for example: CTX, OXA, PER, GES; CTX-M 
being the most common12,13. ESBL genes are commonly encoded in plasmids, making 
them transmissible between bacterial hosts via HGT12. 
The appearance of ESBL and the horizontal transfer of ESBL-encoding plasmids and 
transposons narrow the available therapeutic options. It is worth mentioning that ESBL-
producers sometimes also harbour genes that confer resistance to also other antibiotic 
classes, such as fluoroquinolones and aminoglycosides13. During the late 80s, a rise in 
the use of carbapenems, a broad-spectrum β-lactam, took place, as it was the only 
antibiotic left to treat ESBL-producing K. pneumoniae14. As a consequence, 
carbapenem-resistant phenotypes were selected and plasmid-mediated 
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carbapenemases started spreading among bacteria. The most common and prevalent 
carbapenemase is KPC, a β-lactamase able to hydrolase all known β-lactam antibiotics 
and to resist β-lactamase inhibitors15 
Since the therapeutic options to treat K. pneumoniae are limited, phage therapy is 
gaining ground, being a promising alternative. 
2.3 INTRODUCTION ON BACTERIOPHAGES 
Two scientists, Frederick Twort and 
Félix d’ Hérelle, discovered 
bacteriophages in the twentieth 
century. It was Félix d´Hérelle who 
named these new organisms as 
bacteriophages, which literally 
means bacteria-eaters16, and 
published a report describing their 
ability to infect bacteria, replicate 
inside them and kill the cells. Since 
phages are the most abundant and 
genetically diverse organisms, it has 
be estimated that there are more 
than 1031 phages on Earth, they are 
known as the most successful life 
form in the world17. 
The discovery of bacteriophages has allowed us to understand a wide variety of 
biological processes since bacteriophages constitute a reliable biological model16. 
Furthermore, they play an important role in ecology and evolution as they take part in 
biochemical cycles and bacterial diversity18.  
Phages are a heterogeneous group and they can be classified according to their 
genome in RNA or DNA phages and according their morphology in thirteen families 
(Image 2). Generally, phage morphology consists of a hexagonal head-like capsid and a 
tail. Most of the phages (96%) are tailed phages, belonging in the order Caudoviriales, 
whereon they belong in Podoviridae, Myoviridae or Siphoviridae family regarding their 
tail morphology. The rest of the phages, divided into ten families, are cubic, filamentous 
or pleomorphic; some of them can have lipid structures or an envelope. Moreover, their 
genome size is also very variable from 4 kb to up to 600 kb. Despite the genome size, all 
genomes encode genome packing, head, tail, DNA replication, RNA-dependent RNA 
polymerase, transcription regulation and lysis genes19. 
Phages are obligate parasites of bacteria. The host range of these viruses is defined by 
the interaction of the tail structures of the phage and specific receptors on the surface of 
the host bacteria16. There are evidences of phages being restricted to a unique host 
strain while there are others that can infect multiple strains that even belong in different 
species20. 
Phages can have lytic or lysogenic life cycle based on whether they are virulent or 
temperate, respectively. Independently of the life cycle, phages have to recognise 
receptors on the host bacteria to adsorb and infect it. Then, the viral genome is injected 
into the host cell. Subsequently, replication strategy will start. In a lytic process, the viral 
Image 2: Classification of phages according their 
morphology and nucleic acid. From: Shosuke Imai et al. 
Bacteriophage therapy: a revitalized therapy against 
bacterial infectious diseases. J. Infect Chemother, 2005. 
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genome is replicated and new viral proteins are produced. New phage particles are 
formed, and finally, the host is lysed and phage particles are released into the 
environment. On the contrary, lysogenic cycle implies the integration of the viral genome 
in the bacterial genome as a prophage. During this process, the viral genome will 
replicate in unison with the host. Stressful conditions can lead to the exclusion of the 
prophage and initiate the lytic cycle21. 
2.3.1 Importance of phages in bacterial evolution. 
If the phages succeed in infecting bacteria, they can participate in bacterial evolution by 
several mechanisms: (1) phage release via cell lysis leads to the release of host DNA 
fragments, which can be acquired by other bacteria via transformation; (2) host DNA 
fragments or plasmids can be incorporated inside the viral capsids during the assembly 
of the viral particles. Other bacteria via generalized or specific transduction will acquire 
this DNA; (3) toxins or other pathogenic proteins (adhesion factors, superantigens, 
mitotic factors) encoded in the viral genome will be incorporated to the bacterial genome 
during lysogenic life cycle; (4) prophages can induce inversions and deletions in the host 
genome21,16. 
2.3.2 Phage therapy against K. pneumoniae. 
Despite the fact that the term “phage therapy” may seem something novel, the use of 
phages as bactericidal agents has been used for more than ninety years22. Nowadays, 
this approach is gaining more and more attention due to ESBL and carbapenem 
resistance. 
Phage therapy has several advantages over chemotherapy23: (1) during phage therapy, 
a natural bacteria-killer is used so it is effective against antibiotic-resistant strains 
because the mechanism of bacteriolysis differ from the one that uses antibiotics; (2) 
there is a great specificity between phages and bacteria, which implies that eukaryotic 
cells are not affected and, consequently, fewer side effects should be show up; (3) even 
though bacteria can develop resistance to phages, phages can also mutate to defeat 
bacterial resistance; (4) the cost associated with the development of phage therapy is 
cheaper than the discovery of new successful drugs; (5) phages can replicate as long as 
a host is present, leading to an exponential increase in their numbers and therefore 
become available in abundance20.   
There are two different ways to employ phage therapy. The first approach only 
comprises one phage, which is selected by testing the bacteria against a collection of 
phages. The second one consists of a cocktail of different phages. In this case, the 
spectrum of the action mechanism is wider than the activity of a single phage24, since 
each phage may infect using different bacterial receptors and each one may have 
different phage-encoded proteins, such as depolymerases, which help killing bacteria25.  
There is not a common consensus about which approach is the best one. Some 
scientists defend cocktails of phages because it may slow down the evolution of phage-
resistance since if a bacterium develops resistance to one phage it will still be sensitive 
to the other phages26. On the other hand, there are scientists that claim that at certain 
point bacteria will develop resistance to all phages questioning whether it is worthwhile 
to use phage cocktails or a highly specific phage27,28,29. 
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To date, 34 genomes of K. pneumoniae infective phages have been deposited into the 
NCBI database. The K. pneumoniae infective phages described in previous publications 
belong in order Caudoviriales and more specifically, in Podoviridae, Myoviridae or 
Siphoviridae families30,31,32. 
Several research groups have performed controlled animal experiments and have 
provided encouraging data on the potential of phage therapy to treat K. pneumonie33,34. 
Nowadays, phage products are subjected to the antibiotic’s legislation. There is not a 
framework regarding the legal status of phage products and the clinical trials to ensure 
their quality, safety and efficacy for their commercialization. As a consequence, the 
progression of phage therapy is held back35. 
Image 3: Principal process in the study of putative phages for phage therapy. Steps one to six were 
followed throughout this thesis: infective phages were characterized genetically and physically and classified 
according to their characteristics. In addition, one viral genome was annotated. The future line is the 
application of phage therapy for which further studies need to be done. Image made by the author. 
3 AIM 
The aim of this project was to characterize the physical structure along with genomic 
qualities of bacteriophages infecting multidrug-resistant clinical Klebsiella pneumoniae 
isolates in order to determine their potential as therapeutic agents against infections.  
1. Study the ability of each phage to infect Klebsiella pneumoniae. 
2. Isolation of genomic material of bacteriophages along with a restriction enzyme 
analysis to identify each phage and determine their genome size. 
3. Study the physical structure of each bacteriophage by electron microscope. 
4. Determine the phylogenetic classification of each phage based on the first and 
second objectives. 
5. Genome sequencing and manual annotation of one of the studied phages. 
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4 MATERIALS AND METHODS: 
4.1 K. PNEUMONIAE HOST STRAINS. 
The bacterial strains EKP3 and EKP8 were used as hosts of bacteriophages. Both 
strains are resistant to a wide variety of antibiotics (Table 1).  

































































































*ST: sequence type.  
4.2 PHAGE SAMPLES. 
The phages studied in this thesis (Table 2) had been isolated from a water sample from 
Nenäinniemi wastewater treatment plant located in the city of Jyväskylä. 
Table 3: Description of bacteriophages used in this thesis 
PHAGE NAME ISOLATION HOST ISOLATION DATE PHAGE STOCK TITER (pfu*/ml) 
EKP3P1 EKP3 20.3.2017 1,56 x109 
EKP3P2 EKP3 29.5.2017 2,42 x109 
EKP3P4 EKP3 12.6.2017 Not determined 
EKP3P5 EKP3 12.6.2017 4,67 x109 
EKP8P1 EKP8 20.3.2017 Not determined 
EKP8P2 EKP8 29.5.2017 8,2 x108 
EKP8P3 EKP8 12.6.2017 2,2 x108 
EKP8P4 EKP8 12.6.2017 1 x107 
*Plaque-forming unit 
Phage stocks were provided after being prepared as follows: 100 µL from a previous 
phage stock (titre around 108-10 pfu), 200 µL of bacteria strain EKP3 or EKP8 –
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depending on the phage – grown overnight at 37°C, and 3 mL of L-soft agar (0.7% agar) 
were plated on a 1% L-agar plate and incubated at 37°C overnight. 
The soft layer of half-infected plates was scraped into 50 mL tube with 5 mL of L-
medium and incubated with 230 rpm agitation at 37°C for 4 hours. Afterwards, the 
mixture was centrifuged at 4700 rpm at room temperature for 12 min and the phage 
lysate (supernatant) was filtered through a 0.8/0.2 µm filter (32mm Syringe Filter with 
0.8/0.2µm Supor® membrane). Finally, phage titer was assessed (Table 3) as it is 
previously explained. Phage stocks were stored at 4°C.  
Titer of the stock was estimated by plating different concentrations of a phage stock with 
100 µL of EKP3 or EKP8 and 3 mL of L-soft agar (0.7% agar). After growing overnight at 
37°C, the number of plaques were counted. 
!"#$%& !" !"#$%&'
!"#$%& !" !"#$% (!") !10
!"#$%"&' !"#$%& = !"# !"	
Equation 1: equation to calculate a phage stock. 
4.3 PHAGE LYSED PLATES. 
The presence of infective phages was examined as follows: 200 µL of bacterial culture 
(EKP3 or EKP8) was mixed with 3 mL of 0.7% agar and the mixture was poured on 1 % 
agar plate to make double layer agar plates. 50 µL of bacteriophage lysate stock was 
spotted on the plate and incubated at 37°C overnight. By next day, the plates and the 
formed degraded spot were inspected.  
4.4 CHARACTERIZATION OF PHAGE GENOMES 
4.4.1 Genome isolation 
At first, DNA isolation kits were used for phage genome extraction since, in general, 
phages are more likely to be DNA phages rather than RNA phages. RNA isolation kit 
was also tested for phage EKP8P1 genome since DNA isolation was not suitable for its 
genome isolation, as it will be discussed lately. Table 3 gathers the different protocols 
tested for the phages. 
Table 4: Protocols for genomic material isolation are indicated according to each phage. Suitable 











5.8x1010 Phage DNA Isolation Kit (Norgen Biotek Corp). Suitable 
EKP3P2 2x109 Phage DNA Isolation Kit (Norgen Biotek Corp). Suitable 
EKP3P4 4.2x106 DNA isolation with ZnCl2 + DNeasy® Blood & Tissue Kit (QIAGEN) Not Suitable 
EKP3P5 5.4x109 Phage DNA Isolation Kit (Norgen Biotek Corp). Suitable 
EKP8P1 3x109 Phage DNA Isolation Kit (Norgen Biotek Corp). Not suitable 
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7x109 DNA isolation with ZnCl2 + DNeasy® Blood & Tissue Kit (QIAGEN) Not suitable 
7x109 QIAamp Viral RNA Mini Kit (QIAGEN) 
Suitable for DNA 
but not suitable 
for RNA 
7x109 DNA isolation with ZnCl2  Suitable 
EKP8P2 
1x109 DNA isolation kit- Norgen biotek. Corp. Suitable 
2x109 DNA isolation with ZnCl2 + DNeasy® Blood & Tissue Kit (QIAGEN) Not suitable 
EKP8P3 1x108 Phage DNA Isolation Kit (Norgen Biotek Corp). Suitable 
EKP8P4 4,5x108 Phage DNA Isolation Kit (Norgen Biotek Corp). Suitable 
 
4.4.1.1 DNA isolation with Phage DNA Isolation Kit (Norgen Biotek Corp). 
The phage genome was isolated with Phage DNA Isolation Kit (Norgen Biotek Corp). 
DNase and RNase treatments were performed to eliminate host genomic DNA and RNA 
in the sample. 1 µL of DNase (1 mg/mL) and 10 µL of RNase (1 mg/mL) were added to 1 
mL of the phage lysate (see titers in Table 3) and incubated for 45 minutes 37°C.  Then, 
500 µL of Lysis Solution, provided by the kit, were added to the solution and mixed by 
vortexing. 10 µL of proteinase K (20 mg/mL) (Thermo Scientific) were added to the 
mixture and incubated first at 55°C for 15 minutes and then at 65°C for another 15 
minutes to inactivate it. Proteinase K degrades DNAse and RNAse enzymes and most 
importantly, it degrades the viral capsid, made of proteins, so that genome is released 
After incubation time, 320 µL of isopropanol were added to the sample and mixed by 
vortexing. 
Afterwards, recommendations of the supplier were followed. Finally, two sequential 
elutions were performed with 75 µL of PCR grade water.  
4.4.1.2 DNA isolation with ZnCl2 precipitation. 
This protocol is based on protocol by  Santos36. First, 1 mL of L-medium was added to 
1mL of phage lysate in order to have 2 mL sample. As in the previous protocol, DNase 
and RNase treatment were performed in order to avoid host genomic DNA and RNA 
contamination. 2 µL of DNase (1 mg/mL) and 20 µL of RNase (1 mg/mL) were added to 
2 mL of the phage lysate and incubated for 30 minutes at 37°C. 40 µL of freshly filtered 
2 M ZnCl2 were added to the lysate (40 µM final concentration of ZnCl2) and incubated at 
37°C for 5 minutes and centrifuged for 1 minute at 10000 rpm (9.6 x g). The pellet was 
suspended in 1 mL of TES buffer (0.1M Tris-HCl pH=8, 0.1M EDTA and 0.3% SDS), 
filtered with 32mm Syringe Filter with 0.8/0.2µm Supor® membrane (Pall Corporation), 
and incubated at 60°C for 15 minutes. 40 µL of proteinase K (20mg/ml) (Thermo 
Scientific) were added and incubated for 90 minutes at 37°C. 
Right after this precipitation, a purification with DNeasy® Blood & Tissue Kit (QIAGEN) 
was performed to elute the DNA as follows: 1 mL of buffer AL was added and mixed by 
vortexing and then 1 mL of 96% ethanol was added and mixed thoroughly. The whole 
sample was pipetted using 600 µL each time into the column and centrifuged at 6,000 x 
g for 1 minute. 500 µL of buffer AW1 were added and centrifuged at 6,000xg for 1 
minute. 500 µL of buffer AW2 were added and centrifuged twice at 20,000 x g for 3 
minutes. Lastly, two elutions were performed with 75 µL of PCR grade water. 
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This protocol was also performed without using DNeasy® Blood & Tissue Kit (QIAGEN) 
for EKP8P1 as it is described below: after suspending in TES buffer, 120 µL of 3 M 
sodium-acetate (pH=5.2) were added and incubated on ice for 15 minutes. Following, 
sample was centrifuged for 1 minute at 12,000 rpm at 4°C. 
Supernatant was retrieved and precipitated with 1 volume of ice-cold isopropanol and 
stored for 5 minutes on ice. Mixture was centrifuged for 30 minutes at 13,000 rpm and 
4°C. DNA pellet was washed with ice-cold 70% ethanol and centrifuged for 15 minutes 
at 13,000 rpm and 4°C. Pellet was dried at room temperature and dissolved in 20 µL of 
PCR grade water (VWR). 
4.4.1.3 RNA purification. 
Neither of the previous protocols suited EKP8P1 and there was not any TEM image 
available to infer its viral family. Regarding to these facts, an attempt to isolate its 
genome with QIAamp Viral RNA Mini Kit (QIAGEN) was done. As a control, ϕNN Host 
range mutant 2 phage, an RNA phage of Pseudomonas syringae pv. phaseolicola 
HB10Y, was used. The instructions given by the provider were followed. Finally, two 
elutions were performed with 40 µL of PCR grade water by centrifuging at 6,000 x g for 1 
minute. 
4.4.1.4 Measuring the DNA/RNA concentration. 
Certain isolated DNA samples were precipitated with ethanol in order to concentrate 
them following this method. 1/10 volume of 3 M sodium-acetate (pH=4,7) and 2,5 x 
volume of 96% ethanol were added to the samples and incubated for 1 hour in the 
freezer. After that, samples were centrifuged at 13,000 rpm for 30 minutes at 4°C. The 
pellet was washed with 900 µL of 75% ethanol and centrifuged again for 15 minutes at 
4°C. Pellet was dried at room temperature and eluted in 25 µL of PCR grade water and 
incubated at 50°C for 10 minutes. 
DNA samples were measured with Qubit™ dsDNA and RNA HS Assay Kit (Invitrogen) 
following the supplier instructions.  
4.4.2 Restriction enzyme analysis. 
Restriction enzyme analysis was designed to identify each phage and estimate their 
genome size. Different enzymes were tested in this experiment. For phages EKP3P2 
and EKP3P5: NcoI (Fermentas Fast Digest), NotI (Fermentas Fast Digest), NdeI 
(Fermentas Fast Digest), SphI (Fermentas Fast Digest), XhoI (Fermentas Fast Digest), 
PstI (Fermentas), SalI (Fermentas) and EcoRV (Fermentas). For T4, which was used as 
a control, NcoI (Fermentas Fast Digestion), XhoI (Fermentas) and BglII (Fermentas) 
were utilized. Enzymes were chosen according to literature37. For phages EKP3P1, 
EKP8P2, EKP8P3 and EKP8P4 only three enzymes were used according to the first 
results: NdeI (Fermentas Fast Digestion), EcoRV (Fermentas) and SalI (Fermentas). 
Enzyme reactions were performed to 300 ng of DNA in a final volume of 20 µL according 
to manufacturer’s instructions. Each reaction, but NdeI, were performed overnight at 
37°C. Only NdeI reaction was conducted at 37°C for 2 hours. 
After the enzyme digestion, the DNA fragments were separated by electrophoresis in a 
1% agarose gel containing 0,5 µg/mL ethidium bromide in TAE-buffer for 90 minutes at 
90 V and 180 mA. 10 µL of GeneRulerTM 1Kb Plus DNA ladder (Thermo Scientific) was 
used as a size marker. 
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4.4.3 DNase and RNase treatments to purified a sample. 
DNase and RNase treatments were performed to EKP8P1 phage in order to test 
whether it was a DNA or RNA phage. As a control, a previously isolated DNA phage 
(EKP8P3) was used.  
The DNase treatment was performed in 10 µL with: RNase-free DNase I 1 U/µL 
(#ENO521) (Thermo Scientific), 1X reaction buffer with MgCl2 and isolated-DNA from 
EKP8P1 (13.1 ng/µL) and EKP8P3 (16.73 ng/µL). The sample was incubated for 30 
minutes at 37°C. Afterwards, 1 µL of 50 mM EDTA, provided by the supplier, was added 
and incubated for 10 minutes at 65°C. For RNase treatment: 2 µL of RNase A (20 
mg/ml) (Invitrogen by Thermo Fisher Scientific) were added to the sample and incubated 
for 45 minutes at 37°C. 
Mixtures were loaded in 1% agarose gel containing 0.5 µg/mL ethidium bromide in TAE 
buffer and run for 1 hour at 90 V and 180 mA. 
4.5 IMAGE PHAGE MORPHOLOGY 
Phage morphology was imaged with transmission electron microscopy (TEM). The 
morphology was determined and the capsid size was measured using a Jeol Jem 1400 
electron microscope. The size of phage particles were determined from the average of 
eight independent viral particles to get a reliable diameter. 
4.5.1 Phage purification from lysate for tem. 
A high-titre (see Table 3) phage lysate (5 mL) was centrifuged at 25,000 x g (14,500 
rpm) for 2 hours at 4°C. Phage pellet was suspended in 5 mL of filtered (32mm Syringe 
Filter with 0.8/0.2µm Supor® membrane) 0.1M ammonium acetate (pH=7). Two 
consecutive centrifugations were performed at at 25,000 x g for 2 hours at 4°C.The 
phage pellet was suspended in 70 µL of sterile 0.02M potassium phosphate (pH=7.5). 
Samples were stored at 4°C until being analysed. 
4.5.2 Staining for tem. 
TEM is a useful technique that allows analysing the structure of a virus easily and 
quickly. Different dyes and dying times were tested in order to get the best contrast and 
conditions for each phage. Three negative stains were tested: phosphotungstic acid 
(PTA), uranyl acetate and ammonium molibdate stain (the detailed dying protocols are 
given below).  
5 µL of purified phage sample from step 4.5.1 was deposited on Formvar carbon-coated 
200-mesh grid and let dry for 2 minutes. Excess suspension was dried with filter paper. 
The staining was performed with 5 µL of 1% PTA (pH=7) and dried for 2 minutes or 10 
µL of 5% ammonium molibdate (pH=7,5) and dried for 1 minute. In case of uranyl 
acetate, the staining was performed twice with 2 µL of 2% uranyl acetate and dried for 2 
minutes.  
4.6 IN SILICO ANALYSIS OF PHAGE GENOME 
The genome of EKP3P5 was sequenced by using Illumina HiSeq™ 2500 technology 
and the resulted reads were assembled with De Novo Assembly tool of software 
Geneious v. R11 to produce a single contig representing the whole genome of the 
phage. The EKP3P5 genome was scanned for possible open reading frames (ORF) 
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using ORF finder (https://www.ncbi.nlm.nih.gov/orffinder/) according to the bacterial, 
archaeal and plant plastid genetic code and a minimal ORF length of 150 nucleotides.  
In addition, the genome was analysed using GeneMark.hmm38 
(http://opal.biology.gatech.edu/GeneMark/gmhmmp.cgi) for prokaryotes with Klebsiella 
pneumoniae 322 as reference genome and with fgenesV 
(http://www.softberry.com/berry.phtml?topic=virus&group=programs&subgroup=gfindv).
BPROM(http://www.softberry.com/berry.phtml?topic=bprom&group=programs&subgroup
=gfindb) was used to find promoters. Predicted ORF sequences were compared with 




5.1 PHAGE LYSED PLATES. 
The eight studied phages are virulent based on their ability to produce clear lysate 
plates; therefore, they are able to infect their original isolation host strains EKP3 and 
EKP8 K. pneumoniae (Image 4).  
Presence of halos is usually related to proteins that can damage the bacteria by 
affecting the matrix or biofilms. EKP3P4, EKP8P2, EKP8P3 and EKP8P4 phages 
produce clear zones surrounded by small halos. EKP3P1 phage produces a turbid zone 
surrounded by a small halo. EKP3P2 and EKP3P5 phages stand out because they have 
a turbid zone surrounded by a large halo. EKP8P1 phage produces a turbid zone with 
small halos (Image 4). Morphology of the halos depends on the properties of each 
phage as they have been studied using the same medium and conditions. 
 
Image 4: Phage lysed plates. A) 
Infective plates of phages isolated 
with K. pneumoniae EKP3 as a 
host. Phages from left to right: 
EKP3P1, EKP3P2, EKP3P4 and 
EKP3P5. B) Infective plates of 
phages isolated with K. pneumoniae 
EKP8 as a host. Phages from left to 
right: EKP8P1, EKP8P2, EKP8P3 
and EKP8P4. Red arrows indicate a 
prominent second halo of infection. 
 
5.2 GENOME ISOLATION EFFICIENCY 
Genome isolation using Phage DNA Isolation Kit was suitable for most phages. DNA 
isolation with ZnCl2 precipitation and DNeasy® Blood & Tissue Kit was performed with 
phages EKP8P1 and EKP3P4 using EKP8P2 as a control, since it had been previously 
isolated with Phage DNA Isolation Kit and resulted to be a DNA phage. This protocol 





QIAamp Viral RNA Mini Kit was performed 
due to neither of the DNA isolation protocols 
suited EKP8P1. Neither RNA nor DNA were 
isolated from the control (ϕNN Host range 
mutant 2 phage), however 2.86 ng/µL of 
RNA and 12.25 ng/µL of DNA were isolated 
from EKP8P1.  
Considering that at this stage no tested 
nucleic acid extraction methods were 
successful to EKP8P1, a DNase and RNase 
treatment was performed (Image 5) to see 
whether it was a DNA or RNA phage. 
EKP8P3 was used as a DNA phage control; 
however, no RNA phage control was used 
because the RNA isolation protocol did not 
suit the only RNA phage available in the 
laboratory at that time.  
DNase degraded EKP8P1 and EKP8P3 genome since tracks three and six are 
completely clear (Image 5). RNase eliminated the brightest band but not the smear 
(Image 5, tracks four and seven) in both samples. 
DNase and RNase treatments for EKP8P1 and EKP8P3 show a pattern that differs from 
the untreated tracks (Image 5, tracks two and five). This result will be analysed 
afterwards in the discussion. EKP8P1 genome was finally isolated with ZnCl2 
precipitation without using the spin columns.  
5.3 RESTRICTION ENZYME ANALYSIS OF PHAGE DNA 
Phage genomes were subjected to restriction enzyme analysis to determine the 
restriction patterns, estimate their genome size and to see if and how different the 
phages are from each other. This analysis also proves whether the genomes constitute 
of single-stranded or double-stranded DNA.  
First results, carried out with EKP3P2 and EKP3P5 (Image 6A), showed that both 
phages were sensitive to EcoRV, SalI and NdeI but were insensitive to PstI and NcoI. As 
the last two enzymes did not work, they were not tested again in the following analyses. 
EKP3P1, EKP8P2, EKP8P3 and EKP8P4 genomes were sensitive to NdeI, SalI and 
EcoRV (Image 6B and 6C). EKP8P1 was insensitive to HindIII and, unlike the other 
phages, to NdeI (Image 6D). 
Recapitulating, EKP3P2, EKP3P5, EKP3P1, EKP8P2, EKP8P3 and EKP8P4 are 
sensitive to the same enzymes and have a similar pattern, which might indicate that they 
are closely related; however, EKP8P1 is insensitive to those enzymes, which might 
indicate that it is not related to them. 
Getting a restriction pattern means those phages have dsDNA genome as the enzymes 
have cut the samples. Even though the undigested samples only show one patterns, we 
cannot confirm that there is just one type of phage in each stock. It might happen that 
there were two genomes of the same size. 
  
Image 5: Agarose gel electrophoresis for 
DNase and RNase-treated EKP8P1 and 
EKP8P3. Ladder: GeneRulerTM 1Kb Plus DNA 
ladder (Thermo Scientific).  
1 2 3 4 5 6 7 
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Image 6: Agarose gel electrophoresis. DNA restriction endonuclease digestion of EKP3P2 (A), EKP3P5 
(A), T4 (A, B), EKP3P1 (B), EKP8P2 (C), EKP8P3 (C), EKP8P4 (C), EKP8P1 (D). Labels on top of the gels 
show the restriction enzymes used. Ladder: GeneRulerTM 1Kb Plus DNA ladder (Thermo Scientific). 
Phage T4 was used as a control. It was insensitive to XhoI, BglI, NcoI (Image 6A), EcoRI 
and HindIII (Image 6B). These enzymes were chosen because they were supposed to 
cut T4 genome according to literature40 and REBASE41 
(http://rebase.neb.com/rebase/rebase.html). 
On the basis of digestion pattern produced after treating the DNA with SalI, the 
approximate genome size of each phage was estimated as follows: SalI cuts the DNA 
resulting into production of DNA fragments of varying sizes, the addition of those 
fragments is approximately the size of the genome. The estimated genome sizes are: 60 
kb for EKP3P1, 43.2 kb for EKP3P2, 57 kb for EKP3P5, 70 kb for EKP8P2, 65 kb for 
EKP8P3 and 72.5 kb for EKP8P4. 
Genome size of EKP8P1 and EKP3P4 could not be estimated due to none of the 
enzymes used for EKP8P1 were able to cut its genome (Image 6D) and the restriction 
analysis for EKP3P4 did not work successfully (Image 7). Electrophoresis for EKP3P4 
restriction (Image 7) shows blurry patterns because there is a background of DNA or 






Image 7: Agarose gel electrophoresis for restriction enzyme 
analysis of EKP3P4. Labels on top of the gel show the respective 
restriction enzymes used. Ladder: GeneRulerTM 1Kb Plus DNA ladder 
(Thermo Scientific). 
5.4 MORPHOLOGICAL CHARACTERIZATION 
All bacteriophages were examined by transmission 
electron microscope. The best stain for phages EKP3P1, 
EKP3P2 and EKP3P5 was 1% PTA, however, for the rest 
of the phages the best stain was 2% uranyl acetate. 
Staining with ammonium molibdate was not accurate as 
the background was too light, complicating the focus of 
the image. 
Electron microscope reports revealed that seven phages (EKP3P1, EKP3P2, EKP3P4, 
EKP3P5, EKP8P2, EKP8P3 and EKP8P4) have hexagonal heads with non-contractile 
tubular tails and the eighth one, EKP8P1, has an icosahedral head with a small non-
contractile tail (Images 8 and 9). 
According to the morphological characterization (Images 8 and 9), seven out of eight 
phages were classified to virus families in Siphoviridae and, the eight one, in 
Podoviridae (T7-like); all belonging to the order Caudoviriales (Table 4). 
An unexpected phage was discovered while imaging EKP8P1 sample. Phages in the 
sample seemed to have a small non-contractile tail but a long non-contractile-tailed 
phage was found (Image 11). According to its morphological features, it can be classified 
in the order of Caudoviriales and its virus family Siphoviridae. This phage has 
icosahedral head of 81 nm of diameter and an inflexible tail of 135 nm length.  
As there was just one Siphoviridae phage among others Podoviridae phages in the 
sample, it seemed that the new phage could be a prophage. In addition, K. pneumoniae 
strain EKP8 has viral elements in its genome (Table 1). 
Table 4: Morphological characteristics of each phage. The estimated head and tail sizes are shown 
along with genome size. A classification according to morphological criteria is indicated. ND: not 
determined. 
PHAGES ORDER FAMILY GENOME HEAD TAIL 
EKP3P1 Caudoviriales Siphoviridae 60 kb 72 nm 160 nm 
EKP3P2 Caudoviriales Siphoviridae 43,2 kb 73,7 nm 190 nm 
EKP3P4 Caudoviriales Siphoviridae  ND 80 nm 200 nm 
EKP3P5 Caudoviriales Siphoviridae 57 kb 88 nm 206 nm 
EKP8P1 Caudoviriales Podoviridae ND 61,5 nm 23 nm 
EKP8P2 Caudoviriales Siphoviridae 70 kb 69,4 nm 180,5 nm 
EKP8P3 Caudoviriales Siphoviridae 65 kb 67,6 nm 202,7 nm 
EKP8P4 Caudoviriales Siphoviridae 72,5 kb 74 nm 185 nm 
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Image 9: Phages isolated with K. pneumoniae EKP8 as a host. A) EKP8P1 (Podoviridae) stained with 
2% uranyl acetate. Magnification 40000X. B) EKP8P2 (Siphoviridae) stained with 2% uranyl acetate. 
Magnification 25000X.  C) EKP8P3 (Siphoviridae) stained with 2% uranyl acetate. Magnification 25000X. D) 
EKP8P4 (Siphoviridae) stained with 2% uranyl acetate. Magnification 25000X. 
Image 8: Phages isolated with K. pneumoniae strain EKP3 as a host. A) EKP3P1 (Siphoviridae) 
stained with 1% phosphotungstate, Magnification 30000X. B) EKP3P2 (Siphoviridae) stained with 1% 
phosphotungstate, Magnification 30000X. C) EKP3P4 (Siphoviridae) stained with 2% uranyl acetate. 
Magnification 15000X.  D) EKP3P5 (Siphoviridae) stained with 1% phosphotungstate, Magnification 
15000X 
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5.5 IN SILICO ANALYSIS OF PHAGE EKP3P5 GENOME 
EKP3P5 has a DNA genome of 47,622 bp with a 52,47% of G+C content. The servers 
ORF finder, GeneMark.hmm and fgenesV were used to find possible open reading 
frames; as a result, 189, 65 and 77 ORFs were found, respectively. 102 promoters were 
found with BPROM. Putative proteins are presented in the image below (see Table S1 in 
supplementary material for more information):  
Image 10: Representation of manual annotation of EKP3P5 genome. Genome is presented in 5'-3' 
direction. Arrows indicate the direction of the gene but are not related to the gene length. Same colour of the 
arrows indicate that proteins share related functions. Numbers below the line represent the coordinates in 
the EKP3P5 genome. Image made by the author. 
6 DISCUSSION 
Klebsiella pneumoniae is considered as one of the major species of clinical relevance. It 
can be treated with antibiotics, a historically successful tool to treat infectious diseases, 
however, the appearance of antibiotic resistant strains complicates the treatment. As a 
consequence, high rates of mortality and morbidity are associated with this pathogen. 
The failure of new drug discovery programs has resulted in that many research groups 
had turned their attention to phage therapy. The major condition to move forwards in 
phage therapy is the availability of well-characterised phage libraries. Hence, an attempt 
to characterize bacteriophages in order to assess their potential for their use in phage 
therapy has been made in this thesis. 
The studied phages have the ability to infect K. pneumoniae; they are virulent phages 
according to their ability to produce clear lysate plates (Image 4). Two examples of 
enhanced lytic activity are phages EKP3P2 and EKP3P5 since they have a second halo 
surrounding the halo of infection. This halo suggests the ability to produce additional 
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molecules that damage the bacteria by affecting the matrix of K. pneumoniae allowing a 
better approach to infect the cells, and also, as the cell is less protected, these 
molecules enhance the activity of antibiotics and the immune system. The other phages 
only form the zone of infection, which means that those phages are effective in infecting 
the bacteria but not effectively producing other molecules28,25.  
After confirming that the phages could infect the bacterium of interest, the next step was 
the characterization of the genetic and physical structure. Starting with the genetic 
analysis, many protocols were used to isolate the genomic material, as there was not a 
single protocol that suited all the phages. Commercial Phage DNA Isolation Kit was 
suitable for most of the phages (Table 3).  
EKP8P1 behaved differently from the other phages, since it could not be imaged with the 
TEM and its genome could not be isolated with the same DNA isolation protocols used 
for other phages. In addition to that, both RNA and DNA were isolated from the sample 
with the QIAamp Viral RNA Mini Kit. In order to clear matters up, DNase and RNase 
treatments (Image 5) were performed to confirm whether EKP8P1 had a DNA or RNA 
genome.  
DNase treatment degraded the genomic material entirely in EKP8P1, and also, as it was 
expected, in EKP8P3 since it was used as a positive control. RNase, in both phages, 
eliminated the brightest band but not the smear. According to these results, it was 
certainly sure that the RNase was contaminated with some DNase. The RNA isolated 
from EKP8P1 sample could be a false positive result or a contamination from the host. 
At this point, even though DNA was isolated with a modified ZnCl2 precipitation protocol, 
no statement can be done about the genomic material of EKP8P1. Further studies need 
to be performed to confirm whether it is a DNA or RNA phage, for example, the 
DNase/RNase treatment should be repeated with uncontaminated reagents. 
The electrophoresis of EKP3P4 genome revealed a white smearing background. This 
background can be degraded DNA from the host or the phage or a contamination of 
proteins   (Image 7). The DNase/RNase treatment may have degraded the phage 
genome or have not degraded the host genome. The same conditions were performed 
with all phages indicating that this phage may be more sensitive to this treatment or the 
amount of host genome in the sample was bigger than in the other ones. As the 
background impairs to see the digestion pattern to estimate the genome, further 
research is needed to determine the genome size.  
For phages EKP3P1, EKP3P2, EKP3P4, EKP8P2, EKP8P3 and EKP8P4 the isolation 
and enzyme digestion of DNA was performed successfully (Images 6A, 6B, 6C). 
Restriction profile confirmed that the genomes of all these seven phages comprised 
dsDNA molecules of approximately 40-70 kb in size (Table 4). 
DNA samples of Siphoviridae phages (EKP3P1, EKP3P2, EKP3P4, EKP3P5, EKP8P2, 
EKP8P3 and EKP8P4) were sensitive to NdeI, SalI and EcoRV and showed a different 
but closely related restriction pattern. This provides evidences of being closely related, 
hence it seemed that they all belong to the same viral family.  
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Siphoviridae Klebsiella phages KP16 and KP36, isolated by Kesik-Szeloch et al, are also 
sensitive to EcoRV and insensitive to NcoI37. The restriction pattern of EcoRV for KP16 
and KP36 is closely related to the pattern of EcoRV for the studied phages in this thesis. 
This supports the hypothesis that similar restriction patterns can be an evidence of 
family relation. 
Podoviridae phage EKP8P1 was insensitive to HindIII and NdeI (Image 6D). Podoviridae 
Klebsiella phages KP34 and KP32, isolated by Kesik-Szeloch et al, are sensitive and 
insensitive to HindIII37, respectively. Differences in sensitivity to restriction 
endonucleases among phages belonging to the same family might show the ability of 
these phages to face with the bacterial defences. This agree with the fact that T7-like 
virus, which belong to Podoviridae family, have a wide variety of strategies to overcome 
restriction modification system42. As none of the endonucleases provided a digestion 
pattern to estimate the genome, further research is needed to determine the genome 
size of EKP8P1. 
T4 phage was used as a positive control during the whole thesis, however, it is worth 
mentioning that it has not been a suitable positive control for DNA phages, as the 
restriction enzymes did not work. There was not another known DNA phage available at 
that moment in the laboratory, so further experiments must be performed with another 
phage. 
Bacteriophages are usually classified according to morphological criteria rather than 
molecular data43 because there are not satisfying genetic markers and there are slight 
differences among the genomes of tailed-phages44.  
Considering that 96% of bacteriophages belong to Caudoviriales order44 characterized 
by dsDNA genomes inside of an icosahedral capsid and the presence of contractile or 
non-contractile tails, it was not a surprise that TEM revealed that the phages studied in 
this thesis belonged to it (Image 8 and 9). Caudoviriales order is subdivided into three 
families: Siphoviridae, Myoviridae and Podoviridae. 
According to ICTV (International Committee on Taxonomy of Virus), Siphoviridae family 
have a non-contractile, long, thin, 65-570x7-10 nm tails that can be flexible or non-
flexible and icosahedral heads of 60 nm in diameter. Myoviridae family have contractile, 
rigid, long, thick, 80-455x16-20 nm tails with variable size and shape of heads. Lastly, 
Podoviridae family have a non-contractile tail about 20x8 nm and an icosahedral capsid 
of 60 nm in diameter. 
All phages were examined using a negative stain in which the specimen, in this case the 
phages, appears light against the dark surrounding background. This technique is based 
on the ability of the stain to scatter electrons strongly and adsorb to biological sample. 
Best TEM images for phages EKP3P1, EKP3P2 and EKP3P5 (Image 8A, 8B and 8D) 
were obtained with 1% PTA. This anion comprises twelve tungsten atoms linked by 
oxygen atoms and the phosphorus atoms in the centre of the molecule. Its dense 
electron density due to the presence of 12 tungsten atoms with an atomic number of 74 
is the base of its use as a negative stain. The rest of phages were stained with 2% 
uranyl acetate (Image 8C, 9A, 9B, 9C and 9D). This compound produces the highest 
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electron density due to the atomic weight of 238 Da of uranium. It can bind to proteins, 
lipids with sialic acid carboxyl groups and nucleic acid phosphate groups of DNA and 
RNA. Our images with 2% uranyl acetate seem to have reacted as a positive staining as 
the capsids are stained in black, but the reason could be that the phages had a tiny 
break in their capsids so uranyl acetate was able to enter inside the capsid and interact 
with the proteins or the phosphate groups of DNA. Staining with 5% was not accurate for 
the phages studied in this thesis. This result can be explained with the electron density 
of ammonium molibdate: as this compound has a lower electron density than the other 
tested stains, the image contrast is lower. 
Comparing the TEM images and DNA isolation results with the classification provided by 
ICTV it was assumed that phages EKP3P1, EKP3P2, EKP3P4, EKP3P5, EKP8P2, 
EKP8P3 and EKP8P4 belong to Siphoviridae family and phage EKP8P1 to Podoviridae 
family. All the viruses could be classified into the order Caudoviriales.  
Only one long-tailed phage was found while 
imaging EKP8P1 sample (Image 11), which is 
likely to be a prophage, a phage that was 
integrated in the host genome but released 
eventually. This hypothesis is supported by the 
fact that there are bacteriophages inserted in the 
genome of the strain EKP8 and the rest of the 
imaged viral particles were Podoviridae phages. It 
is not likely to be a contamination because there 
should have been more tailed-phages and 
several plaque isolations steps were performed to 
purify the phage stock. Taking this into 
consideration, new phages should be 
characterised using bacteria unable to release 
prophages. In this way, there would be no 
hesitation between a prophage and the studied 
phage.  
The genome of EKP3P5 was analysed further after sequencing. Sequencing revealed 
that EKP3P5 has a genome of 47,6 kb in size with a G+C content of 52,47%.  The 
genome size is comparable with the values estimated by ICTV for Siphoviridae family.  
Siphoviridae bacteriophages organize their genome in a way that related functions 
cluster together45 as it can be appreciated in image 11. The genome has been divided 
into nine different parts regarding the pathway in which the predicted proteins are 
involved. The most important putative proteins encoded in EKP3P5 genome are 
discussed below. 
The hypothetical presence of terminase proteins, tape measure proteins and portal 
proteins along with tail and coat proteins gives us a hint about the assembly of the 
phage. According to the literature, the assembly process could be performed as follows: 
coat proteins may start forming the icosahedral capsid and join the portal protein, which 
will interact lately with the terminase protein. These two last proteins are involved in the 
recognition of the viral DNA and form a powerful molecular motor that helps 
     500nm
Image 11: Prophage found while 
analysing EKP8P1 sample. Stained with 
2% uranyl acetate. Magnification 15000X. 
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translocating the DNA inside the head. Once DNA packaging is complete, tail proteins 
are recruited. Tape measure protein indicates the tail length and facilitates DNA transit 
to the cell cytoplasm during infection 44,45. 
An Ig-like virion protein was found in the genome of EKP3P5, which may be involved in 
the recognition of the host cell surface receptors. As it has been previously described, 
these proteins act in the first step of infection and limit the host range.  
A putative integrase was found in EKP3P5 genome. The integrase is an enzyme that 
recognises a site-specific sequence in both the viral and bacterial genomes and allows 
the phage to integrate inside the host chromosome46. According to that, it seems that 
this phage may be a temperate phage, which enters in lysogenic cycle. There are 
several reasons why to avoid using temperate phages in phage therapy: (1) temperate 
phages may encode toxins and virulence factor, therefore, when the prophage is 
established the bacteria can turn into a more pathogenic strain; (2) the bacteria become 
immune to the superinfection for related phages once the lysogen is established; (3) 
temperate phages are capable of transduction, which could lead in the antibiotic 
resistance dissemination26. 
The ability of EKP3P5 to produce a second halo of infection has been previously 
discussed. The annotation of its genome revealed, that this phage encoded two putative 
proteins related with the degradation of the capsule of K. pneumoniae: holin and 
endolysin, two peptidoglycan hydrolases. Holin acts by creating holes in the host cell 
membrane allowing endolysin to reach the outlayer of peptidoglycan and degrade it. 
Endolysin has been proposed to be an alternative to antibiotics. While β-lactam 
antibiotics inhibit the synthesis of peptidoglycan, endolysin degraded the bacterial cell 
directly independently the bacterium is growing or not23.   
Despite the fact that phage therapy is a promising alternative to face infectious diseases, 
it is necessary to be aware of its limitations. Bacteria can develop resistance to phages 
by means of different mechanisms such as adsorption resistance, restriction-
modification and CRISPR-Cas system27,47. Taking into account that the massive use of 
antibiotics has led to the emergence of antibiotic resistance strains, the massively used 
of phages can also develop resistance. However, phages have several mechanisms to 
defeat bacterial defences and develop resistance that are summarized below. 
To achieve replication, phages have to attach to the host cell. Phages can modify their 
receptors to recognise the bacteria. They also encode enzymes, such as 
endosialidases, which degrade the bacterial wall and gain access when the bacteria 
shield its receptor to reduce the susceptibility to phage infection. Phages have 
developed many anti-restriction mechanisms to face restriction-modification systems. 
Some of these anti-restriction mechanisms are: inhibitor proteins (Ocr, DarA and DarB) 
of the restriction system, reduction of the restriction sites and incorporation of modified 
nucleotides in the viral genome. Finally, phages can encode anti-CRISPR proteins that 
impair the CRISPR interference48(Image 12). 
The use of bacteriophages in biotechnological processes requires more knowledge of 
phage characteristics such us host range, latent period, growth time and resistance to 
stress conditions such as different temperature or pH. Further experiments need to be 
performed for a clinical use of phages26. 
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Phage therapy has many challenges that need to be overcome. Phages can trigger 
immune and allergic reactions; in addition, antibodies can neutralize the phages leading 
to a decrease therapeutic effect. Phage therapy rarely if ever results in side effects as for 
example, intensification of the pain24. The use of phages as a therapeutic approach can 
lead to the emergence of resistant strains. As it has been previously discussed, bacteria 
and phages are a clear example of coevolution; therefore, phages can mutate to adapt 
the new host. The most serious concern about phage therapy is transfer of toxin genes 
via transduction; this can modify the host in a way that the bacteria become more 
pathogenic. This problem can be overcome by the selection of phages without the ability 
of transduction or by using genetically modified phages23. 
Image 12: Overview of the viral mechanisms to face bacterial defences. A: Adsorption resistance. 
Bacteria can alter their cell surface receptors to reduce the susceptibility to phage infection. Nevertheless, 
phages can alter their receptor binding structures to match the new bacterial receptor. B: Restriction-
modification system (RMS). This system consists of an endonuclease that recognises specific sites in 
foreign DNA sequences and cuts them and a methyltransferase that modifies the host DNA by transferring a 
methyl group and prevents its cut. It blocks new viral infections by degrading the viral DNA. There are four 
major groups of RMS based on their structure, recognition site, cofactor requirements and cleavage 
position42. Phages can synthetize proteins (DarA/B, Lar/Ral) to block the methyltrasnferase and 
endonuclease activities. C: Representation of the different steps in the CRISPR-Cas system. CRISPR-
Cas system is considered the immune system of bacteria as it can target and cleave viral DNA in a 
sequence-specific manner. The CRISPR interference takes place when the sequence of the protospacer is 
identical to the spacer hence the Cas proteins cleave the plasmid or viral DNA avoiding the replication. 
Phages encode anti-CRISPR proteins, which impair the formation of the CRISPR-Cas complex and the 






• EKP3P1, EKP3P2, EKP3P4 and EKP3P5 infect EKP3 K. pneumoniae strain while 
EKP8P1, EKP8P2, EKP8P3 and EKP8P4 infect EKP8 K. pneumoniae strain. 
• There is not a single DNA isolation or staining protocol that suits all phages. 
Protocols need to be optimized for each phage. 
• Seven phages (EKP3P1, EKP3P2, EKP3P4, EKP3P5, EKP8P2, EKP8P3 and 
EKP8P4) have a dsDNA genome. No statement can be made about the genetic 
material of EKP8P1. Further experiments must be performed to verify the genetic 
material of EKP8P1. Genome sizes vary from 40 kb to 73 kb. 
• All bacteriophages belong to Caudoviriales order and were classified in Siphoviridae 
(EKP3P1, EKP3P2, EKP3P4, EKP3P5, EKP8P2, EKP8P3 and EKP8P4) and 
Podoviridae (EKP8P1) families regarding their physical structure.  
• The analysis of the phage genome provides essential information about the life 
cycle of the virus. This allows identifying temperate phages (EKP3P5) and 
dismissing them for phage therapy. 
 
CONCLUSIONES 
• Los fagos EKP3P1, EKP3P2, EKP3P4 y EKP3P5 infectan la cepa de K. 
pneumoniae EKP3, mientras que los fagos EKP8P1, EKP8P2, EKP8P3 y EKP8P4 
infectan la cepa de K. pneumoniae EKP8. 
• No hay un protocolo de aislamiento de material genético o tinción óptimo para todos 
los fagos. Los protocolos tienen que ser optimizados de manera individual para 
cada virus. 
• Siete fagos (EKP3P1, EKP3P2, EKP3P4, EKP3P5, EKP8P2, EKP8P3 y EKP8P4) 
tienen un genoma caracterizado por una doble cadena de ADN. En el caso de 
EKP8P1 no se puede asegurar la naturaleza de su genoma. Se debe realizar un 
estudio mas exhaustivo de EKP8P1 para determinar la naturaliza de su genoma. El 
tamaño de los genomas varía de 40 kb a 73 kb.  
• Todos los fagos pertenecen al reino Caudoviriales y a las familias Siphoviridae 
(EKP3P1, EKP3P2, EKP3P4, EKP3P5, EKP8P2, EKP8P3 y EKP8P4)  y 
Podoviridae (EKP8P1). 
• El estudio del genoma permite conocer información importante sobre el ciclo de 
vida de los fagos, permitiendo identificar a los fagos atemperados (EKP3P5), los 
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